Perspective of cytokine regulation for periodontal treatment: Fibroblast biology

Journal of Periodontology

Volumn 74, Issue 1, 2003, Pages 103-110

  Takashiba, Shogo ^a   Naruishi, Koji ^a   Murayama, Yoji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Cytokines; Fibroblasts; Immune response; Interleukin 1 ; Interleukin 6; Periodontal diseases pathogenesis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTIINFECTIVE AGENT; BETA DEFENSIN; CHLORHEXIDINE GLUCONATE; COLLAGEN; CYTOKINE; ETANERCEPT; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA RECEPTOR BLOCKING AGENT; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARTILAGE CELL; CELL ACTIVATION; CELL FUNCTION; CELL SECRETION; CELL STIMULATION; COLLAGEN DEGRADATION; DRUG DESIGN; DRUG MECHANISM; ENZYME DEGRADATION; ENZYME RELEASE; FIBROBLAST; GINGIVA; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INHIBITION KINETICS; LYMPHOCYTE; MONOCYTE; PERIODONTAL DISEASE; PERIODONTITIS; PROTEIN BINDING; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; TARGET CELL;

ANTI-INFLAMMATORY AGENTS; BIOLOGY; COLLAGENASES; CYTOKINES; FIBROBLASTS; GINGIVA; GINGIVITIS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; PERIODONTAL DISEASES; PERIODONTITIS; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037268875     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2003.74.1.103     Document Type: Review

References (72)

1. Takashiba S, Myokai F, Ohyama H, et al. Concepts for the biological treatment of periodontal diseases. In: Bartold PM, Ishikawa I, Sirirat M, eds. Progress of Periodontal Research and Practice in Asian Paciflc Countries. Brisbane, Australia: Asian Pacific Society of Periodontology; 2000: 42-52.
2. Listgarten MA. Pathogenesis of periodontitis. J Clin Periodontol 1986;13:418-430.
3. Jotwani R, Cutler CW. Adult periodontitis-specific bacterial infection or chronic inflammation? J Med Microbiol 1998;47:187-188.
4. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357.
5. Everts V, van der Zee E, Creemers L, Beertsen W. Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem J 1996;28:229-245.
6. Lekic PC, Pender N, McCulloch CA. Is fibroblast heterogeneity relevant to the health, diseases, and treatments of periodontal tissues? Crit Rev Oral Biol Med 1997;8:253-268.
7. Hassell TM. Tissues and cells of the periodontium. Periodontol 2000 1993;3:9-38.
8. Haase HR, Clarkson RW, Waters MJ, Bartold PM. Growth factor modulation of mitogenic responses and proteoglycan synthesis by human periodontal fibroblasts. J Cell Physiol 1998;174:353-361.
9. Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol 1993;64:474-484.
10. Havemose-Poulsen A, Holmstrup P. Factors affecting IL-1-mediated collagen metabolism by fibroblasts and the pathogenesis of periodontal disease: A review of the literature. Crit Rev Oral Biol Med 1997;8:217-236.
11. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001;45:101-106.
12. Tipton DA, Dabbous MK. Autocrine transforming growth factor beta stimulation of extracellular matrix production by fibroblasts from fibrotic human gingiva. J Periodontol 1998;69:609-619.
13. Morita Y, Yamamura M, Kawashima M, et al. Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. Rheumatol Int 2001;20:49-54.
14. Seitz M, Loetscher P, Dewald B, Towbin H, Gallati H, Baggiolini M. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Eur J Immunol 1995;25:1129-1132.
15. Maini RN, Feldmann M. Cytokine therapy in rheumatoid arthritis. Lancet 1996;348:824-825.
16. Assuma R, Oates T, Cochran D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1998;160:403-409.
17. Graves DT, Delima AJ, Assuma R, Amar S, Oates T, Cochran D. Interleukin-1 and tumor necrosis factor antagonists inhibit the progression of inflammatory cell infiltration toward alveolar bone in experimental periodontitis. J Periodontol 1998;69:1419-1425.
18. Chiang CY, Kyritsis G, Graves DT, Amar S. Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infect Immun 1999;67:4231-4236.
19. Delima AJ, Oates T, Assuma R, et al. Soluble antagonists to interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. J Clin Periodontol 2001;28:233-240.
20. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147.
21. Boch JA, Wara-aswapati N, Auron PE. Interleukin 1 signal transduction-current concepts and relevance to periodontitis. J Dent Res 2001;80:400-407.
22. Sims JE, March CJ, Cosman D, et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988;241:585-589.
23. Sims JE, Acres RB, Grubin CE, et al. Cloning the interleukin 1 receptor from human T cells. Proc Natl Acad Sci (USA) 1989;86:8946-8950.
24. McMahan CJ, Slack JL, Mosley B, et al. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. Embo J 1991;10:2821-2832.
25. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995;270:13757-13765.
26. Sims JE, Gayle MA, Slack JL, et al. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci (USA) 1993;90:6155-6159.
27. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science 1993;261:472-475.
28. Colotta F, Mantovani A. Induction of the interleukin-1 decoy receptor by glucocorticoids. Trends Pharmacol Sci 1994;15:138-139.
29. Bossu P, Visconti U, Ruggiero P, et al. Transfected type II interleukin-1 receptor impairs responsiveness of human keratinocytes to interleukin-1. Am J Pathol 1995;147: 1852-1861.
30. Re F, Sironi M, Muzio M, et al. Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: A surface "receptor" with anti-interleukin-1 function. J Exp Med 1996;183:1841-1850.
31. Groves RW, Sherman L, Mizutani H, Dower SK, Kupper TS. Detection of interleukin-1 receptors in human epidermis. Induction of the type II receptor after organ culture and in psoriasis. Am J Pathol 1994;145:1048-1056.
32. Garlind A, Brauner A, Hojeberg B, Basun H, Schultzberg M. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. Brain Res 1999;826:112-116.
33. Chou HH, Takashiba S, Maeda H, et al. Induction of intracellular interleukin-1 beta signals via type II interleukin-1 receptor in human gingival fibroblasts. J Dent Res 2000;79:1683-1688.
34. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-422.
35. Ryffel B, Mihatsch MJ. TNF receptor distribution in human tissues. Int Rev Exp Pathol 1993;34 (Pt B):149-156.
36. Wajant H, Scheurich P. Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int J Biochem Cell Biol 2001;33:19-32.
37. Gravallese EM, Galson DL, Goldring SR, Auron PE. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res 2001;3:6-12.
38. Seitz M, Loetscher P, Dewald B, et al. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8-markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol 1996;23:1512-1516.
39. Tervahartiala T, Koski H, Xu JW, et al. Tumor necrosis factor-alpha and its receptors, p55 and p75, in gingiva of adult periodontitis. J Dent Res 2001;80:1535-1539.
40. Ohe H, Takashiba S, Naruishi K, et al. Tumor necrosis factor-alpha (TNF-alpha)-induced and interieukin-1 beta (IL-1 beta)-induced shedding of TNF receptors from gingival fibroblasts. J Interferon Cytokine Res 2000;20: 1077-1082.
41. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
42. Taga T, Hibi M, Murakami M, et al. Interleukin-6 receptor and signals. Chem Immunol 1992;51:181-204.
43. Frieling JT, Sauerwein RW, Wijdenes J, Hendriks T, van der Linden CJ. Soluble interleukin 6 receptor in biological fluids from human origin. Cytokine 1994;6:376-381.
44. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem J 1994;300 (Pt 2):281-290.
45. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334 (Pt 2):297-314.
46. Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268:160-167.
47. Naruishi K, Takashiba S, Chou HH, Arai H, Nishimura F, Murayama Y. Role of soluble interleukin-6 receptor in inflamed gingiva for binding of interleukin-6 to gingival fibroblasts. J Periodont Res 1999;34:296-300.
48. Naruishi K, Takashiba S, Nishimura F, et al. Impairment of gingival fibroblast adherence by IL-6/sIL-6R. J Dent Res 2001;80:1421-1424.
49. Rossomando EF, Kennedy JE, Hadjimichael J. Tumour necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol 1990;35:431-434.
50. Stashenko P, Fujiyoshi P, Obernesser MS, Prostak L, Haffajee AD, Socransky SS. Levels of interleukin 1 beta in tissue from sites of active periodontal disease. J Clin Periodontol 1991;18:548-554.
51. Matsuki Y, Yamamoto T, Hara K. Detection of inflammatory cytokine messenger RNA (mRNA)-expressing cells in human inflamed gingiva by combined in situ hybridization and immunohistochemistry. Immunology 1992; 76: 42-47.
52. Lo YJ, Liu CM, Wong MY, Hou LT, Chang WK. Interleukin 1 beta-secreting cells in inflamed gingival tissue of adult periodontitis patients. Cytokine 1999;11:626-633.
53. Okada Y, Nagase H, Harris ED, Jr. Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. J Rheumatol 1987; 14 Spec No:41-42.
54. Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro. J Bone Miner Res 1989;4:113-118.
55. 2 secretion from gingival fibroblasts treated with interleukin-1 beta: Effects of lipid extracts from Porphyromonas gingivalis or calculus. J Periodont Res 2001;36:142-152.
56. Takigawa M, Takashiba S, Myokai F, et al. Cytokine-dependent synergistic regulation of interleukin-8 production from human gingival fibroblasts. J Periodontol 1994;65:1002-1007.
57. 2 inhibits interleukin-6 release but not its transcription in human gingival fibroblasts stimulated with interleukin-1 beta or tumor necrosis factor-alpha. J Periodontol 1994;65:1122-1127.
58. Bozkurt FY, Berker E, Akkus S, Bulut S. Relationship between interleukin-6 levels in gingival crevicular fluid and periodontal status in patients with rheumatoid arthritis and adult periodontitis. J Periodontol 2000;71:1756-1760.
59. Guillot JL, Pollock SM, Johnson RB. Gingival interleukin-6 concentration following phase I therapy. J Periodontol 1995;66:667-672.
60. Klouche M, Bhakdi S, Hemmes M, Rose-John S. Novel path to activation of vascular smooth muscle cells: upregulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol 1999;163: 4583-4589.
61. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916.
62. Elliott MJ, Feldmann M, Maini RN. TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action. Int J Immunopharmacol 1995;17: 141-145.
63. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-6607.
64. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999;26(Suppl. 57): 7-15.
65. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.
66. Dale BA, Kimball JR, Krisanaprakornkit S, et al. Localized antimicrobial peptide expression in human gingiva. J Periodont Res 2001;36:285-294.
67. Weinberg A, Krisanaprakornkit S, Dale BA. Epithelial antimicrobial peptides: Review and significance for oral applications. Crit Rev Oral Biol Med 1998;9:399-414.
68. Hancock RE. Peptide antibiotics. Lancet 1997;349:418-422.
69. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88:553-560.
70. Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998;102:874-880.
71. Mineshiba F, Takashiba S, Mineshiba J, Matsuura K, Kokeguchi S, Murayama Y. Antibacterial activity of synthetic human β defensin-2 against periodontal bacteria. J Int Acad Periodontol; in press.
72. Bonadio J, Smiley E, Patil P, Goldstein S. Localized, direct plasmid gene delivery in vivo: Prolonged therapy results in reproducible tissue regeneration. Nat Med 1999;5:753-759.